| Naslov: | Basophil activation test predicts cetuximab anaphylaxis severity in alpha-gal IgE-positive patients |
|---|
| Avtorji: | ID Kopač, Peter, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Koren, Ana, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Bidovec, Urška, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Košnik, Mitja, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Dejanović, Luka, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Mesti, Tanja, Onkološki inštitut Ljubljana (Avtor)
ID Strojan, Primož, Onkološki inštitut Ljubljana (Avtor)
ID Korošec, Peter, Univerzitetna klinika za pljučne bolezni in alergijo Golnik (Avtor)
ID Ocvirk, Janja, Onkološki inštitut Ljubljana (Avtor) |
|---|
| Datoteke: |  URL - Izvorni URL, za dostop obiščite https://www.mdpi.com/2075-4418/14/13/1403
 PDF - Predstavitvena datoteka, prenos (768,48 KB)
MD5: B0BC46E13AAF68E3295B7020DA5956FB
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKPBAG - Univerzitetna klinika za pljučne bolezni in alergijo Golnik
 OI - Onkološki inštitut Ljubljana
|
|---|
| Povzetek: | Upon first exposure to cetuximab, hypersensitivity reactions can occur. We aimed to assess the utility of the basophil activation test (BAT) to alpha-gal and cetuximab for predicting severe reactions. We prospectively recruited 38 patients and evaluated sIgE to alpha-gal in all patients before the first application of cetuximab. In all alpha-gal-sensitized patients, we evaluated skin tests to meat extracts, gelatine, and cetuximab and performed BAT with alpha-gal and cetuximab. In 24% (9/38) of patients, sIgE to alpha-gal was >0.10 kUA/L, and 8/9 reacted to the cetuximab. Basophil activation tests with alpha-gal were positive in all sensitized patients and were higher in those with severe reactions (18.3% in grade 4 [n = 4] vs. 1.8% in grade 2 [n = 3] or no reaction [n = 1] at 3.3 ng/mL of alpha-gal; p = 0.03). All patients with severe grade 4 reactions had a positive CD63 BAT response to cetuximab compared to patients with moderate or no reaction, who all had negative BAT (57.7% vs. 0.9% at 500 µg/mL, 63.2% vs. 4.1% at 100 µg/mL, 58.2% vs. 2.7% at 10 µg/mL, and 32.1% vs. 3.3% at 1 µg/mL of cetuximab, respectively; p ≤ 0.001). In summary, before initiating cetuximab treatment, sIgE to alpha-gal should be assessed in all patients. To predict the severity of the reaction and to assess the risk of cetuximab-induced anaphylaxis, we should perform BATs with alpha-gal or more discriminative BATs with cetuximab. |
|---|
| Ključne besede: | alpha-gal, baseline serum tryptase, basophil activation test, cetuximab, drug allergy |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Poslano v recenzijo: | 10.05.2024 |
|---|
| Datum sprejetja članka: | 26.06.2024 |
|---|
| Datum objave: | 01.07.2024 |
|---|
| Leto izida: | 2024 |
|---|
| Št. strani: | str. [1]-11 |
|---|
| Številčenje: | Vol. 14, issue 13, [article no.] 1403 |
|---|
| PID: | 20.500.12556/DiRROS-23077  |
|---|
| UDK: | 61 |
|---|
| ISSN pri članku: | 2075-4418 |
|---|
| DOI: | 10.3390/diagnostics14131403 |
|---|
| COBISS.SI-ID: | 201818371 |
|---|
| Avtorske pravice: | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
|---|
| Opomba: | Nasl. z nasl. zaslona;
Opis vira z dne 15. 7. 2024;
|
|---|
| Datum objave v DiRROS: | 22.07.2025 |
|---|
| Število ogledov: | 565 |
|---|
| Število prenosov: | 258 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
